US6090834A
(en)
*
|
1993-05-21 |
2000-07-18 |
G.D. Searle & Co. |
Substituted oxazoles for the treatment of inflammation
|
US5380738A
(en)
*
|
1993-05-21 |
1995-01-10 |
Monsanto Company |
2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents
|
US6613789B2
(en)
|
1994-07-28 |
2003-09-02 |
G. D. Searle & Co. |
Heterocyclo-substituted imidazoles for the treatment of inflammation
|
US5616601A
(en)
*
|
1994-07-28 |
1997-04-01 |
Gd Searle & Co |
1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
|
JP2636819B2
(ja)
|
1994-12-20 |
1997-07-30 |
日本たばこ産業株式会社 |
オキサゾール系複素環式芳香族化合物
|
JP3181190B2
(ja)
*
|
1994-12-20 |
2001-07-03 |
日本たばこ産業株式会社 |
オキサゾール誘導体
|
AU5860396A
(en)
*
|
1995-05-19 |
1996-11-29 |
G.D. Searle & Co. |
Substituted oxazoles for the treatment of inflammation
|
US6512121B2
(en)
|
1998-09-14 |
2003-01-28 |
G.D. Searle & Co. |
Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
|
US6515014B2
(en)
|
1995-06-02 |
2003-02-04 |
G. D. Searle & Co. |
Thiophene substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
|
AU5886296A
(en)
|
1995-06-02 |
1996-12-18 |
G.D. Searle & Co. |
Heterocyclo substituted hydroxamic acid derivatives as cyclo oxygenase-2 and 5-lipoxygenase inhibitors
|
US5643933A
(en)
*
|
1995-06-02 |
1997-07-01 |
G. D. Searle & Co. |
Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors
|
CA2224517A1
(en)
*
|
1995-06-12 |
1996-12-27 |
G.D. Searle & Co. |
Compositions comprising a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor
|
US5700816A
(en)
*
|
1995-06-12 |
1997-12-23 |
Isakson; Peter C. |
Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor
|
JPH11507669A
(ja)
*
|
1995-06-12 |
1999-07-06 |
ジー.ディー.サール アンド カンパニー |
シクロオキシゲナーゼ−2インヒビターとロイコトリエンb▲下4▼受容体アンタゴニストの組合せによる炎症と炎症関連疾患の治療
|
US5968974A
(en)
*
|
1995-07-19 |
1999-10-19 |
Merck & Co., Inc. |
Method of treating colonic adenomas
|
US6593361B2
(en)
|
1995-07-19 |
2003-07-15 |
Merck & Co Inc |
Method of treating colonic adenomas
|
WO1997012863A1
(en)
|
1995-09-29 |
1997-04-10 |
Shionogi & Co., Ltd. |
α-SUBSTITUTED BENZYL HETEROCYCLIC DERIVATIVES, INTERMEDIATES FOR PRODUCING THE SAME, AND PESTICIDES CONTAINING THE SAME AS ACTIVE INGREDIENT
|
CA2234633A1
(en)
*
|
1995-10-17 |
1997-04-24 |
G.D. Searle & Co. |
Method of detecting cyclooxygenase-2
|
DE69709069T2
(de)
|
1996-02-13 |
2002-07-04 |
Searle & Co |
Zusammensetzungen mit immunosuppressiven wirkungen, welche 5-lipoxygenase-inhibitoren und cyclooxygenase-2-inhibitoren enthalten
|
ATE223732T1
(de)
*
|
1996-02-13 |
2002-09-15 |
Searle & Co |
Arzneimittelkombinationen mit immunosuppressiven wirkungen welche cyclooxygenase-2 inhibitoren und leukotrien lta4 hydrase-inhibitoren enthalten
|
JP2000505445A
(ja)
|
1996-02-13 |
2000-05-09 |
ジー.ディー.サール アンド カンパニー |
シクロオキシゲナーゼ―2インヒビターとロイコトリエンb▲下4▼受容体アンタゴニストの投与の免疫抑制作用
|
ES2125161B1
(es)
*
|
1996-03-21 |
1999-11-16 |
Grupo Farmaceutico Almirall S |
Nuevos derivados de 2-(3h)-oxazolona.
|
US5908858A
(en)
*
|
1996-04-05 |
1999-06-01 |
Sankyo Company, Limited |
1,2-diphenylpyrrole derivatives, their preparation and their therapeutic uses
|
PT892791E
(pt)
|
1996-04-12 |
2003-06-30 |
Searle & Co |
N-¬¬4-(5-metil-3-fenilisoxazol-4-il|fenil|sulfonil-propilamida e seu sal de sodio como pro-farmacos de inibidores de cox-2
|
US6677364B2
(en)
*
|
1998-04-20 |
2004-01-13 |
G.D. Searle & Co. |
Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors
|
US5945538A
(en)
*
|
1996-06-28 |
1999-08-31 |
American Cyanamid Company |
Ammonium oxazole and amino oxazolium intermediates, methods for the preparation thereof and the use therefor in the manufacture of insecticidal arylpyrroles
|
US5750726A
(en)
*
|
1996-06-28 |
1998-05-12 |
American Cyanamid Company |
Process for the manufacture of 2-aryl-5-perfluoroalkylpyrrole derivatives and intermediates useful therefor
|
US5925773A
(en)
*
|
1996-06-28 |
1999-07-20 |
American Cyanamid Company |
Ammonium oxazole and amino oxazolium intermediates, methods for the preparation thereof and the use thereof in the manufacture of insecticidal arylpyrroles
|
US5777132A
(en)
*
|
1996-06-28 |
1998-07-07 |
American Cyanamid Company |
Process for the manufacture of 2-aryl-5 perfluoroalkylpyrrole derivatives
|
FR2753449B1
(fr)
*
|
1996-09-13 |
1998-12-04 |
Union Pharma Scient Appl |
Nouveaux derives 3,4-diaryloxazolone, leurs procedes de preparation, et leurs utilisations en therapeutique
|
IL128568A0
(en)
|
1996-10-15 |
2000-01-31 |
Searle & Co |
Use of cyclooxygenase-2 inhibitors for the manufacture of a medicament for the treatment and prevention of neoplasia
|
NZ500141A
(en)
*
|
1997-04-18 |
2002-05-31 |
G |
Method of using cyclooxygenase-2 inhibitors in the prevention of cardiovascular disorders
|
ES2131015B1
(es)
*
|
1997-09-12 |
2000-03-01 |
Almirall Prodesfarma Sa |
Nuevos derivados de 2-(3h)-oxazolona, procedimientos para su preparacion y su empleo en composiciones farmaceuticas.
|
US6025353A
(en)
*
|
1997-11-19 |
2000-02-15 |
G.D. Searle & Co. |
Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents
|
US6887893B1
(en)
*
|
1997-12-24 |
2005-05-03 |
Sankyo Company, Limited |
Methods and compositions for treatment and prevention of tumors, tumor-related disorders and cachexia
|
IT1303672B1
(it)
|
1998-07-28 |
2001-02-23 |
Nicox Sa |
Sali nitrati di farmaci attivi nei disordini ossei
|
US20030013739A1
(en)
*
|
1998-12-23 |
2003-01-16 |
Pharmacia Corporation |
Methods of using a combination of cyclooxygenase-2 selective inhibitors and thalidomide for the treatment of neoplasia
|
US6833373B1
(en)
|
1998-12-23 |
2004-12-21 |
G.D. Searle & Co. |
Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
|
US6649645B1
(en)
*
|
1998-12-23 |
2003-11-18 |
Pharmacia Corporation |
Combination therapy of radiation and a COX-2 inhibitor for treatment of neoplasia
|
US6858598B1
(en)
|
1998-12-23 |
2005-02-22 |
G. D. Searle & Co. |
Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
|
US20010024664A1
(en)
*
|
1999-03-19 |
2001-09-27 |
Obukowicz Mark G. |
Selective COX-2 inhibition from edible plant extracts
|
FR2800373B1
(fr)
*
|
1999-10-27 |
2001-12-07 |
Oreal |
Procede de preparation d'oxazoles trisubstitues
|
IL144760A0
(en)
*
|
1999-12-08 |
2002-06-30 |
Pharmacia Corp |
Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect
|
EP1246621A4
(de)
|
1999-12-23 |
2004-11-24 |
Nitromed Inc |
Nitrosierte und nitrosylierte cyclooxygenase-2-inhibitoren, zusammensetzungen und methoden für deren verwendung
|
DE10001166A1
(de)
|
2000-01-13 |
2001-07-19 |
Merckle Gmbh |
Anellierte Pyrrolverbindungen, diese enthaltende pharmazeutische Mittel und deren Verwendung
|
WO2001081332A2
(en)
*
|
2000-04-25 |
2001-11-01 |
Pharmacia Corporation |
2-fluorobenzenesulfonyl compounds for the treatment of inflammation
|
PE20020146A1
(es)
*
|
2000-07-13 |
2002-03-31 |
Upjohn Co |
Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
|
EP1299123A2
(de)
*
|
2000-07-13 |
2003-04-09 |
Pharmacia Corporation |
Verwendung von cox-2 hemmern zur behandlung und vorbeugung von cox-2-abhängigen augenkrankheiten
|
CN100488500C
(zh)
*
|
2000-07-20 |
2009-05-20 |
劳拉斯有限公司 |
Cox-2抑制剂预防免疫缺陷的用途
|
US6716829B2
(en)
|
2000-07-27 |
2004-04-06 |
Pharmacia Corporation |
Aldosterone antagonist and cyclooxygenase-2 inhibitor combination therapy to prevent or treat inflammation-related cardiovascular disorders
|
WO2002017896A2
(en)
*
|
2000-08-29 |
2002-03-07 |
Peter Van Patten |
Combination for the treatment of migraine comprising a cyclooxygenase-2 inhibitor and acetylsalicylic acid
|
JP2004517838A
(ja)
*
|
2000-12-15 |
2004-06-17 |
ファルマシア・コーポレーション |
非食用植物抽出物による選択的cox−2阻害
|
EP1401460A2
(de)
*
|
2000-12-15 |
2004-03-31 |
Pharmacia Corporation |
Selektive cox-2-hemmung aus pflanzenextrakten
|
US7115565B2
(en)
*
|
2001-01-18 |
2006-10-03 |
Pharmacia & Upjohn Company |
Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
|
JP2004522754A
(ja)
*
|
2001-02-02 |
2004-07-29 |
ファルマシア・コーポレーション |
月経困難症の治療および予防のための組み合わせ治療としてシクロオキシゲナーゼ‐2阻害剤および性ステロイドを使用する方法
|
PE20021017A1
(es)
|
2001-04-03 |
2002-11-24 |
Pharmacia Corp |
Composicion parenteral reconstituible
|
US20030105144A1
(en)
|
2001-04-17 |
2003-06-05 |
Ping Gao |
Stabilized oral pharmaceutical composition
|
US6673818B2
(en)
|
2001-04-20 |
2004-01-06 |
Pharmacia Corporation |
Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation
|
US20030153801A1
(en)
*
|
2001-05-29 |
2003-08-14 |
Pharmacia Corporation |
Compositions of cyclooxygenase-2 selective inhibitors and radiation for inhibition or prevention of cardiovascular disease
|
US20030129186A1
(en)
|
2001-07-25 |
2003-07-10 |
Biomarin Pharmaceutical Inc. |
Compositions and methods for modulating blood-brain barrier transport
|
UA80682C2
(en)
*
|
2001-08-06 |
2007-10-25 |
Pharmacia Corp |
Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition
|
AR038957A1
(es)
|
2001-08-15 |
2005-02-02 |
Pharmacia Corp |
Terapia de combinacion para el tratamiento del cancer
|
US20030236308A1
(en)
*
|
2001-09-18 |
2003-12-25 |
Pharmacia Corporation |
Compositions of cyclooxygenase-2 selective inhibitors and acetaminophen for treatment and prevention of inflammation, inflammation-mediated disorders and pain
|
US20030114483A1
(en)
*
|
2001-09-18 |
2003-06-19 |
Pharmacia Corporation |
Compositions of chromene cyclooxygenase-2 selective inhibitors and acetaminophen for treatment and prevention of inflammation, inflammation-mediated disorders and pain
|
WO2003049678A2
(en)
|
2001-12-06 |
2003-06-19 |
Merck & Co., Inc. |
Mitotic kinesin inhibitors
|
US20040062823A1
(en)
*
|
2001-12-13 |
2004-04-01 |
Obukowicz Mark G. |
Selective cox-2 inhibition from non-edible plant extracts
|
US20040126438A1
(en)
*
|
2001-12-13 |
2004-07-01 |
Obukowicz Mark G. |
Selective cox-2 inhibition from plant extracts
|
TW562937B
(en)
*
|
2002-03-26 |
2003-11-21 |
Nanya Technology Corp |
Method for fast determining defect type of word line
|
US7329401B2
(en)
*
|
2002-04-15 |
2008-02-12 |
The Regents Of The University Of California |
Cyclooxygenase-2 selective agents useful as imaging probes and related methods
|
AU2003215867A1
(en)
*
|
2002-04-22 |
2003-11-03 |
Pfizer Products Inc. |
Indol-2-ones as selective inhibitors of cyclooxygenase-2
|
WO2003095623A2
(en)
*
|
2002-05-10 |
2003-11-20 |
The Trustees Of Columbia University In The City Of New York |
Genetically engineered cell lines and systems for propagating varicella zoster virus and methods of use thereof
|
US20030225054A1
(en)
*
|
2002-06-03 |
2003-12-04 |
Jingwu Duan |
Combined use of tace inhibitors and COX2 inhibitors as anti-inflammatory agents
|
US7087630B2
(en)
*
|
2002-06-27 |
2006-08-08 |
Nitromed, Inc. |
Cyclooxygenase 2 selective inhibitors, compositions and methods of use
|
JP2005535642A
(ja)
|
2002-06-28 |
2005-11-24 |
ニトロメッド インコーポレーティッド |
オキシムおよび/またはヒドラゾンを含有するニトロソ化および/またはニトロシル化シクロオキシゲナーゼ−2選択的阻害剤、組成物、および使用方法
|
WO2004004833A1
(en)
*
|
2002-07-02 |
2004-01-15 |
Pharmacia Corporation |
Use of cyclooxygenase-2 selective inhibitors and thrombolytic agents for the treatment or prevention of a vaso-occlusive event
|
PL377657A1
(pl)
|
2002-12-13 |
2006-02-06 |
Warner-Lambert Company Llc |
Ligand Ó-2-Ű do leczenia dolegliwości dolnych dróg moczowych
|
PL377427A1
(pl)
*
|
2002-12-19 |
2006-02-06 |
Pharmacia Corporation |
Sposoby i kompozycje do leczenia infekcji wirusem opryszczki z zastosowaniem inhibitorów selektywnych względem cyklooksygenazy-2 lub inhibitorów cyklooksygenazy-2 w połączeniu ze środkami przeciwwirusowymi
|
US20040171664A1
(en)
*
|
2002-12-20 |
2004-09-02 |
Pharmacia Corporation |
Compositions of cyclooxygenase-2 selective inhibitors and selective serotonin reuptake inhibitors for the treatment or prevention of a vaso-occlusive event
|
TW200505446A
(en)
*
|
2003-01-17 |
2005-02-16 |
Fuj Isawa Pharmaceutical Co Ltd |
Inhibitor of cox
|
US7772188B2
(en)
|
2003-01-28 |
2010-08-10 |
Ironwood Pharmaceuticals, Inc. |
Methods and compositions for the treatment of gastrointestinal disorders
|
US20050026902A1
(en)
*
|
2003-01-31 |
2005-02-03 |
Timothy Maziasz |
Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents
|
CA2519189C
(en)
*
|
2003-05-07 |
2012-07-17 |
Osteologix A/S |
Water-soluble strontium salts for use in treatment of cartilage and/or bone conditions
|
PT2266585E
(pt)
*
|
2003-05-07 |
2013-07-09 |
Osteologix As |
Sais de estrôncio hidrossolúveis para uso no tratamento de afeções cartilagíneas e/ou ósseas
|
US20050065154A1
(en)
*
|
2003-06-24 |
2005-03-24 |
Pharmacia Corporation |
Treatment of migraine accompanied by nausea with a combination of cyclooxygenase-2 selective inhibitors and anti-nausea agents
|
JP2007502831A
(ja)
*
|
2003-08-20 |
2007-02-15 |
ニトロメッド インコーポレーティッド |
ニトロソ化およびニトロシル化心血管化合物、組成物、ならびに使用方法
|
US20070238740A1
(en)
*
|
2003-08-28 |
2007-10-11 |
Nitromed, Inc. |
Nitrosated And Nitrosylated Cardiovascular Compounds, Compositions And Methods Of Use
|
US7067159B2
(en)
*
|
2003-12-05 |
2006-06-27 |
New Chapter, Inc. |
Methods for treating prostate cancer with herbal compositions
|
US7070816B2
(en)
*
|
2003-12-05 |
2006-07-04 |
New Chapter, Inc. |
Methods for treating prostatic intraepithelial neoplasia with herbal compositions
|
US20090131342A1
(en)
*
|
2004-01-22 |
2009-05-21 |
Nitromed, Inc. |
Nitrosated and/or nitrosylated compounds, compositions and methods of use
|
JP2007518788A
(ja)
|
2004-01-22 |
2007-07-12 |
ファイザー・インク |
バソプレッシンのアンタゴニスト活性を阻害するトリアゾール誘導体
|
FR2866340B1
(fr)
*
|
2004-02-13 |
2006-11-24 |
Sanofi Synthelabo |
Derives d'oxazole, leur preparation et leur utilisation en therapeutique.
|
AU2005247943A1
(en)
|
2004-05-23 |
2005-12-08 |
Gerard M. Housey |
Theramutein modulators
|
PE20060362A1
(es)
*
|
2004-05-24 |
2006-05-15 |
Irm Llc |
Compuestos de oxazol como moduladores de ppar
|
KR20070039885A
(ko)
|
2004-07-01 |
2007-04-13 |
머크 앤드 캄파니 인코포레이티드 |
유사분열 키네신 억제제
|
US7622142B2
(en)
*
|
2004-09-14 |
2009-11-24 |
New Chapter Inc. |
Methods for treating glioblastoma with herbal compositions
|
US8067464B2
(en)
|
2004-10-04 |
2011-11-29 |
Nitromed, Inc. |
Compositions and methods using apocynin compounds and nitric oxide donors
|
EP1814535A4
(de)
*
|
2004-11-08 |
2008-06-04 |
Nitromed Inc |
Nitrosierte und nitrosylierte verbindungen, zusammensetzungen und verfahren zur behandlung von augenkrankheiten
|
AU2005306629A1
(en)
*
|
2004-11-15 |
2006-05-26 |
Nicox S.A. |
Diuretic compounds comprising heterocyclic nitric oxide donor groups, compositions and methods of use
|
CA2595579A1
(en)
*
|
2005-01-21 |
2006-07-27 |
Nitromed, Inc. |
Cardiovascular compounds comprising heterocyclic nitric oxide donor group compositions and methods of use
|
WO2007086884A2
(en)
*
|
2005-02-16 |
2007-08-02 |
Nitromed, Inc. |
Organic nitric oxide donor salts of antimicrobial compounds, compositions and methods of use
|
US7521435B2
(en)
*
|
2005-02-18 |
2009-04-21 |
Pharma Diagnostics, N.V. |
Silicon containing compounds having selective COX-2 inhibitory activity and methods of making and using the same
|
EP1858863A1
(de)
*
|
2005-02-28 |
2007-11-28 |
Nitromed, Inc. |
Stickstoffmonoxid-verstärkende gruppen enthaltende cardiovaskuläre verbindungen, zusammensetzungen und anwendungsverfahren
|
US20090215838A1
(en)
*
|
2005-03-09 |
2009-08-27 |
Nitromed, Inc. |
Organic nitric oxide enhancing salts of angiotensin ii antagonists, compositions and methods of use
|
AR054336A1
(es)
*
|
2005-03-30 |
2007-06-20 |
Astion Dev As |
Tratamiento de enfermedades dermatologicas y del prurito
|
AU2006228869A1
(en)
|
2005-03-30 |
2006-10-05 |
Astion Pharma A/S |
Oxaprozin or a closely related compound for the treatment of eczema
|
AU2006239221C1
(en)
|
2005-04-28 |
2012-08-16 |
Otsuka Pharmaceutical Co., Ltd. |
Pharma-informatics system
|
EP1888050B1
(de)
|
2005-05-17 |
2012-03-21 |
Merck Sharp & Dohme Ltd. |
Cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexanepropansäure zur Behandlug von Krebs
|
US8431110B2
(en)
|
2005-05-23 |
2013-04-30 |
Hmi Medical Innovations, Llc. |
Compounds and method of identifying, synthesizing, optimizing and profiling protein modulators
|
EP1883614A4
(de)
*
|
2005-05-23 |
2010-04-14 |
Nicox Sa |
Organische stickoxide verbessernde salze aus nichtsteroiden entzündungshemmenden verbindungen sowie zusammensetzungen und verwendungsverfahren dafür
|
EP1915157A4
(de)
*
|
2005-08-02 |
2010-09-01 |
Nicox Sa |
Stickoxidverstärkende antimikrobielle verbindungen, zusammensetzungen und verwendungsverfahren
|
TW200804345A
(en)
*
|
2005-08-30 |
2008-01-16 |
Novartis Ag |
Substituted benzimidazoles and methods of preparation
|
AU2006299383A1
(en)
*
|
2005-10-04 |
2007-04-12 |
Nitromed, Inc. |
Methods for treating respiratory disorders
|
WO2007059311A2
(en)
*
|
2005-11-16 |
2007-05-24 |
Nitromed, Inc. |
Furoxan compounds, compositions and methods of use
|
US20090275070A1
(en)
*
|
2005-11-23 |
2009-11-05 |
Housey Gerard M |
Compounds and Methods of Identifying, Synthesizing, Optimizing and Profiling Protein Modulators
|
EP1968584A2
(de)
*
|
2005-12-20 |
2008-09-17 |
Nitromed, Inc. |
Stickoxid-verstärkende glutaminsäure-verbindungen, zusammensetzungen und anwendungsverfahren
|
WO2007075542A2
(en)
*
|
2005-12-22 |
2007-07-05 |
Nitromed, Inc. |
Nitric oxide enhancing pyruvate compounds, compositions and methods of use
|
EP1978964A4
(de)
|
2006-01-24 |
2009-12-09 |
Merck & Co Inc |
Jak2-tyrosinkinase-hemmung
|
GB0603041D0
(en)
|
2006-02-15 |
2006-03-29 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
CA2647859C
(en)
|
2006-03-29 |
2016-01-05 |
Nitromed, Inc. |
Nitric oxide enhancing prostaglandin compounds, compositions and methods of use
|
WO2007121484A2
(en)
|
2006-04-19 |
2007-10-25 |
Novartis Ag |
6-o-substituted benzoxazole and benzothiazole compounds and methods of inhibiting csf-1r signaling
|
WO2008033466A2
(en)
*
|
2006-09-14 |
2008-03-20 |
Combinatorx (Singapore) Pre. Ltd. |
Compositions and methods for treatment of viral diseases
|
EP2946778A1
(de)
|
2006-09-22 |
2015-11-25 |
Merck Sharp & Dohme Corp. |
Behandlungsverfahren mit verwendung von fettsäuresyntheseinhibitoren
|
US20080208179A1
(en)
*
|
2006-10-26 |
2008-08-28 |
Reliant Technologies, Inc. |
Methods of increasing skin permeability by treatment with electromagnetic radiation
|
US20110218176A1
(en)
|
2006-11-01 |
2011-09-08 |
Barbara Brooke Jennings-Spring |
Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
|
EP2125021B8
(de)
|
2006-12-22 |
2012-02-15 |
Recordati Ireland Limited |
Kombinationstherapie für erkrankungen der unteren harnwege mit alpha 2delta liganden und nsar
|
PL2805945T3
(pl)
|
2007-01-10 |
2019-09-30 |
Msd Italia S.R.L. |
Indazole podstawione grupą amidową jako inhibitory polimerazy poli(adp-rybozy) - (parp)
|
JP2010516679A
(ja)
*
|
2007-01-19 |
2010-05-20 |
マリンクロット インコーポレイテッド |
診断用および治療用シクロオキシゲナーゼ−2結合リガンド
|
KR101514853B1
(ko)
|
2007-03-01 |
2015-04-24 |
노파르티스 아게 |
Pim 키나제 억제제 및 이들의 사용 방법
|
US8795627B2
(en)
|
2007-03-21 |
2014-08-05 |
Raptor Pharmaceuticals Inc. |
Treatment of liver disorders by administration of RAP conjugates
|
MX2009012679A
(es)
|
2007-05-21 |
2009-12-11 |
Novartis Ag |
Inhibidores de csf-1r, composiciones y metodos de uso.
|
CA2690191C
(en)
|
2007-06-27 |
2015-07-28 |
Merck Sharp & Dohme Corp. |
4-carboxybenzylamino derivatives as histone deacetylase inhibitors
|
US20090011060A1
(en)
*
|
2007-07-06 |
2009-01-08 |
Peter Koepke |
Campsiandra angustifolia extract and methods of extracting and using such extract
|
US20090017140A1
(en)
*
|
2007-07-09 |
2009-01-15 |
Peter Koepke |
Maytenus abenfolia extract and methods of extracting and using such extract
|
BRPI0814542A2
(pt)
|
2007-07-12 |
2014-09-30 |
Tragara Pharmaceuticals Inc |
Métodos e composições para o tratamento de câncer, tumores e desordens relacionadas a tumores
|
US20090035395A1
(en)
*
|
2007-08-01 |
2009-02-05 |
Peter Koepke |
Spondias mombin l. extract and methods of extracting and using such extract
|
JP5411141B2
(ja)
|
2007-09-10 |
2014-02-12 |
カルシメディカ,インク. |
細胞内カルシウムを調節する化合物
|
US7879369B2
(en)
*
|
2007-09-18 |
2011-02-01 |
Selvamedica, Llc |
Combretum laurifolium Mart. extract and methods of extracting and using such extract
|
EP2247185B1
(de)
|
2008-03-03 |
2014-04-16 |
Tiger Pharmatech |
Tyrosinkinase-hemmer
|
MX2011002149A
(es)
|
2008-08-27 |
2011-04-05 |
Calcimedica Inc |
Compuestos que modulan el calcio intracelular.
|
AU2010216512B2
(en)
|
2009-02-20 |
2016-06-30 |
2-Bbb Medicines B.V. |
Glutathione-based drug delivery system
|
IL255113B
(en)
|
2009-05-06 |
2022-09-01 |
Laboratory Skin Care Inc |
Preparations for administration through the skin that include complexes of an active substance with calcium phosphate and methods of using them
|
WO2011046771A1
(en)
|
2009-10-14 |
2011-04-21 |
Schering Corporation |
SUBSTITUTED PIPERIDINES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF
|
JP6112486B2
(ja)
|
2010-04-27 |
2017-04-12 |
カルシメディカ,インク. |
細胞内カルシウムを調節する化合物
|
EP2563759B1
(de)
|
2010-04-27 |
2022-04-06 |
Calcimedica, Inc. |
Verbindungen als modulatoren von intrazellulärem calcium
|
CN103038229B
(zh)
*
|
2010-05-26 |
2016-05-11 |
桑诺维恩药品公司 |
杂芳基化合物及其使用方法
|
EP2584903B1
(de)
|
2010-06-24 |
2018-10-24 |
Merck Sharp & Dohme Corp. |
Neue heterozyklische verbindungen als erk-hemmer
|
JP6043285B2
(ja)
|
2010-08-02 |
2016-12-14 |
サーナ・セラピューティクス・インコーポレイテッドSirna Therapeutics,Inc. |
低分子干渉核酸(siNA)を用いたカテニン(カドヘリン結合型タンパク質)β1(CTNNB1)遺伝子発現のRNA干渉媒介性阻害
|
LT2606134T
(lt)
|
2010-08-17 |
2019-07-25 |
Sirna Therapeutics, Inc. |
Hepatito b viruso (hbv) geno raiškos slopinimas, tarpininkaujant rnr interferencijai naudojant mažą interferuojančią nukleorūgštį (sina)
|
EP2608669B1
(de)
|
2010-08-23 |
2016-06-22 |
Merck Sharp & Dohme Corp. |
Neue pyrazolo-[1,5-a-]pyrimidinderivate als mtor-hemmer
|
US9079891B2
(en)
|
2010-08-27 |
2015-07-14 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
US8946216B2
(en)
|
2010-09-01 |
2015-02-03 |
Merck Sharp & Dohme Corp. |
Indazole derivatives useful as ERK inhibitors
|
EP2615916B1
(de)
|
2010-09-16 |
2017-01-04 |
Merck Sharp & Dohme Corp. |
Kondensierte pyrazolderivate als neue erk-hemmer
|
US20120077778A1
(en)
|
2010-09-29 |
2012-03-29 |
Andrea Bourdelais |
Ladder-Frame Polyether Conjugates
|
US9260471B2
(en)
|
2010-10-29 |
2016-02-16 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
|
WO2012087772A1
(en)
|
2010-12-21 |
2012-06-28 |
Schering Corporation |
Indazole derivatives useful as erk inhibitors
|
CA2831730A1
(en)
|
2011-04-21 |
2012-10-26 |
Piramal Enterprises Limited |
A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
|
WO2013063214A1
(en)
|
2011-10-27 |
2013-05-02 |
Merck Sharp & Dohme Corp. |
Novel compounds that are erk inhibitors
|
EP2773207B1
(de)
|
2011-10-31 |
2018-03-07 |
Merck Sharp & Dohme Corp. |
Aminopyrimidinone als interleukinrezeptor-assoziierte kinaseinhibitoren
|
US20150299696A1
(en)
|
2012-05-02 |
2015-10-22 |
Sirna Therapeutics, Inc. |
SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
|
CN105050598B
(zh)
|
2012-09-28 |
2018-04-27 |
默沙东公司 |
作为erk抑制剂的新型化合物
|
WO2014059333A1
(en)
|
2012-10-12 |
2014-04-17 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
RU2660349C2
(ru)
|
2012-11-28 |
2018-07-05 |
Мерк Шарп И Доум Корп. |
Композиции и способы для лечения злокачественной опухоли
|
WO2014100065A1
(en)
|
2012-12-20 |
2014-06-26 |
Merck Sharp & Dohme Corp. |
Substituted imidazopyridines as hdm2 inhibitors
|
EP2951180B1
(de)
|
2013-01-30 |
2018-05-02 |
Merck Sharp & Dohme Corp. |
2,6,7,8-substituierte purine als hdm2-inhibitoren
|
US20160166576A1
(en)
|
2013-07-11 |
2016-06-16 |
Merck Sharp & Dohme Corp. |
Substituted amidopyrazole inhibitors of interleukin receptor-associated kinases (irak-4)
|
US20160194368A1
(en)
|
2013-09-03 |
2016-07-07 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
US9611263B2
(en)
|
2013-10-08 |
2017-04-04 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
JO3589B1
(ar)
|
2014-08-06 |
2020-07-05 |
Novartis Ag |
مثبطات كيناز البروتين c وطرق استخداماتها
|
WO2016144849A1
(en)
|
2015-03-12 |
2016-09-15 |
Merck Sharp & Dohme Corp. |
Thienopyrazine inhibitors of irak4 activity
|
US10155765B2
(en)
|
2015-03-12 |
2018-12-18 |
Merck Sharp & Dohme Corp. |
Carboxamide inhibitors of IRAK4 activity
|
EP3267996B1
(de)
|
2015-03-12 |
2020-11-11 |
Merck Sharp & Dohme Corp. |
Pyrazolopyrimidinhibitoren der irak4-aktivität
|
EP3292213A1
(de)
|
2015-05-04 |
2018-03-14 |
Academisch Medisch Centrum |
Biomarker für den nachweis von aspirinunempfindlichkeit
|
CN104892495B
(zh)
*
|
2015-06-08 |
2017-04-26 |
青岛农业大学 |
一种新的合成含吡啶类化合物的方法
|
US10947234B2
(en)
|
2017-11-08 |
2021-03-16 |
Merck Sharp & Dohme Corp. |
PRMT5 inhibitors
|
WO2020033282A1
(en)
|
2018-08-07 |
2020-02-13 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
US20210309688A1
(en)
|
2018-08-07 |
2021-10-07 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|